Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire • 05/13/25
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 05/08/25
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025Business Wire • 04/29/25
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy PointsInvestors Business Daily • 04/26/25
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/22/25
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 03/26/25
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025Business Wire • 03/25/25
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market RallyInvestors Business Daily • 03/24/25
Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even NvidiaInvestors Business Daily • 02/25/25
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?Zacks Investment Research • 02/18/25
International Markets and Exelixis (EXEL): A Deep Dive for InvestorsZacks Investment Research • 02/17/25
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025Business Wire • 02/15/25